STAA
STAAR Surgical Company
Healthcare · Medical Instruments & Supplies · NGM
$29.99
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$1.6B
Total market value of the company
Trailing P/E
N/A
Forward P/E
31.79
Based on estimated future earnings — lower means cheaper
Rev Growth
+119.6%
Year-over-year revenue change
Profit Margin
-7.2%
How much profit the company keeps from each dollar of revenue
ROE
-6.0%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$29.00
-3% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 9 analysts covering this stock
About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

https://www.staar.com

Country: United States Employees: 921 Industry: Medical Instruments & Supplies
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
0.059
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0038
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.219
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-15.0%
Historical annualised return based on price data
Max Drawdown
-68.3%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
14
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.20
Moves slightly more than the broader market
52W High
$35.87
16% below the year high
52W Low
$15.59
92% above the year low
Avg Volume
1,198,073
Average daily shares traded — higher means easier to buy and sell
Short Ratio
6.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
24.9%
Very high short interest — potential squeeze candidate
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.42
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
10.58
Heavy leverage — higher financial risk if revenues decline
Current Ratio
5.12
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
4.09
Like current ratio but excludes inventory — stricter test
Gross Margin
76.9%
Revenue left after cost of goods — higher means pricing power
Operating Margin
18.7%
Profit from core operations before interest and tax
Free Cash Flow
$-17,512,250
Negative — the business is spending more than it generates
Revenue (TTM)
$290M
Total revenue over the last 12 months
Net Income
$-21,031,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
9
Target High
$40.00
Target Median
$29.00
Target Low
$23.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.